AFICC Welcomes New Board Members
Updated: Feb 1, 2022
We are excited to welcome Kay Ekstrom to AFICC’s Board. Kay brings a wealth of experience in Non-Profit leadership! She is the founding member of the National Association of Christian Child and Family Agencies and served as the Association’s Executive Director. She is a member of the Board of Directors of the Children’s Action Alliance, Steps of Faith and Adoptive Families Coalition. Kay’s passion for children stems from her own experiences as a foster and adoptive parent. Kay and her husband Chuck, who passed away in 2016, have four daughters, three sons, eight grandchildren and two great-grandchildren. Kay resides in Phoenix, Arizona. Thank you Kay for joining the ICC Family—we are thankful for your giftedness and passion for children!
Bryan Klein is currently a Research Director at Gartner Inc., focusing on Quality and Supply Chain Management. Prior to joining Gartner, Mr. Klein worked in a variety of industries while living in China, Africa and North America, helping companies establish systems and processes to increase performance and efficiencies.
Most recently, Bryan directed a nonprofit malnutrition initiative in Southeast Africa that manufactured fortified peanut-butter for malnourished children. Some of Mr. Klein’s previous work experience includes the International Crisis Group in Beijing, China and Spire Research & Consulting in Shanghai, China. Bryan studied international affairs at Georgetown University, focusing on US-China relations, and at Fudan University, receiving a Masters in International Politics.
Dr. Zhang has been working in the pharmaceutical industry for more than 20 years. She has extensive experience on preclinical drug development for anti-cancer therapies, starting from early-stage research, project initiation, all the way down to late-stage toxicology evaluation. She has led and participated in multiple projects which have successfully advanced into clinical trials, including both small molecules and biotherapeutics. She published numerous papers in world top journals and presented at various international meetings. Recently, she has been focusing on the development of COVID-19 treatment since the outbreak of the pandemic. She joined Sorrento Therapeutics in 2013 and is currently an Executive director of Toxicology and ADC drug development. Before that, she worked at Biogen Idec, Conforma Therapeutics and Dupont Pharmaceuticals.Dr. Zhang received her Ph.D. in Biochemistry and Molecular Biology from University of Pittsburgh. She did her post-doctoral research at the Burnham Institute in San Diego.